10.2 Chronic Obstructive Pulmonary Disease (COPD) & Inhaler Delivery Systems

10.2 Chronic Obstructive Pulmonary Disease (COPD) & Inhaler Delivery Systems

Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable, and treatable chronic respiratory disease characterized by persistent, often progressive airflow limitation resulting from a combination of small airway disease (obstructive bronchiolitis) and parenchymal tissue destruction (emphysema). In Canada, COPD represents the fourth leading cause of mortality and the number one contributor to avoidable medical hospitalizations. The Canadian Thoracic Society (CTS) guidelines and the Global Initiative for Chronic Obstructive Lung Disease (GOLD) consensus provide an integrated clinical pathway focusing on smoking cessation, optimal inhaled bronchodilation, exacerbation mitigation, and correct inhaler device selection.

---

Diagnostic Criteria & Clinical Assessment of COPD

COPD should be suspected in any individual aged 40 years or older who presents with persistent, progressive dyspnea (worsening with physical exertion), chronic cough (productive or non-productive), chronic sputum production, or a history of exposure to environmental or occupational risk factors—predominantly tobacco smoking (≥ 20 pack-years), biomass fuel smoke, or occupational dust and chemical fumes. A genetic deficiency in alpha-1 antitrypsin (AAT) should be screened in individuals who develop early-onset emphysema (< 45 years of age) or have a family history of premature COPD.

Objective Diagnostic Hallmark: Spirometry

Physical examination signs (wheezing, hyperinflation, decreased breath sounds, pursed-lip breathing) lack sensitivity and specificity. Spirometry performed after administering a fast-acting bronchodilator (salbutamol 400 mcg) is mandatory to confirm the diagnosis.

                               COPD SPIROMETRIC DIAGNOSTIC CUTOFF
                               
                    Patient ≥ 40 years with Dyspnea, Chronic Cough, Smoking History
                                                  │
                                                  ▼
                                     Post-Bronchodilator Spirometry
                                                  │
                         ┌────────────────────────┴────────────────────────┐
                         ▼                                                 ▼
               FEV1/FVC < 0.70                                   FEV1/FVC ≥ 0.70
                         │                                                 │
                         ▼                                                 ▼
             DIAGNOSIS CONFIRMED (COPD)                           COPD Excluded
           Persistent Fixed Airflow Limitation               Consider Asthma or other causes
                         │
                         ▼
           Grade Airflow Limitation Severity (Based on Post-BD FEV1 % predicted)
           • GOLD 1 (Mild):        FEV1 ≥ 80% predicted
           • GOLD 2 (Moderate):    50% ≤ FEV1 < 80% predicted
           • GOLD 3 (Severe):      30% ≤ FEV1 < 50% predicted
           • GOLD 4 (Very Severe): FEV1 < 30% predicted

Assessing Symptom Burden & Exacerbation Risk

Airflow obstruction alone correlates imperfectly with clinical symptoms and quality of life. Current Canadian practice classifies patients based on two core axes:

1. Symptom Burden:
   • Modified Medical Research Council (mMRC) Dyspnea Scale: Scored 0 to 4 (0: breathless only with strenuous exercise; 1: shortness of breath hurrying on level ground or walking up slight hill; 2: walks slower than contemporaries on level ground due to breathlessness or stops for breath; 3: stops for breath after walking ~100 meters or after a few minutes on level ground; 4: too breathless to leave the house or breathless dressing/undressing). An $mMRC \ge 2$ indicates high dyspnea.
   • COPD Assessment Test (CAT): Comprehensive 8-item questionnaire scored from 0 to 40. A CAT score $\ge 10$ reflects high symptom burden.
2. Exacerbation Risk:
   • Low Risk: 0 or 1 moderate exacerbation in the past 12 months (treated with outpatient antibiotics/steroids) not resulting in hospital admission.
   • High Risk: ≥ 2 moderate exacerbations OR ≥ 1 exacerbation requiring hospital admission within the preceding year.

---

Maintenance Pharmacotherapy Algorithm

The primary goals of chronic maintenance pharmacotherapy are symptom reduction (relieving breathlessness, improving exercise tolerance and health status) and risk reduction (preventing disease progression, preventing and treating exacerbations, and reducing mortality). Inhaled bronchodilators are the central pharmacological axis.

                         CTS 2023 COPD MAINTENANCE PHARMACOTHERAPY

              Confirm post-bronchodilator FEV1/FVC < 0.70; assess symptoms, health status
                                 and exacerbation risk (past 12 months)
                                                  │
        ┌─────────────────────────────────────────┼─────────────────────────────────────────┐
        ▼                                         ▼                                         ▼
  MILD SYMPTOMS                        MODERATE-SEVERE SYMPTOMS                 MODERATE-SEVERE SYMPTOMS
  (CAT < 10, mMRC < 2)                 (CAT ≥ 10 or mMRC ≥ 2)                   (CAT ≥ 10 or mMRC ≥ 2)
  FEV1 ≥ 80%, low risk                 FEV1 < 80%, LOW exacerbation risk        HIGH exacerbation risk*
        │                                         │                                         │
        ▼                                         ▼                                         ▼
  LAMA or LABA                           LAMA/LABA dual therapy                  LAMA/LABA/ICS TRIPLE therapy
  monotherapy                            (single inhaler)                        (single inhaler; mortality benefit)
                                                                                            │
                                                         Still exacerbating on triple therapy?
                                                                                            ▼
                                                         Add azithromycin maintenance (or roflumilast /
                                                         N-acetylcysteine in chronic bronchitis)

  * High risk = 2 or more moderate exacerbations, or 1 or more severe exacerbation (hospital/ED), in the past year.
  CTS recommends AGAINST theophylline, maintenance oral corticosteroids, and ICS monotherapy.

1. Long-Acting Bronchodilator Monotherapy (LAMA or LABA)

• Long-Acting Muscarinic Antagonists (LAMA): Tiotropium (Spiriva), Umeclidinium (Incruse), Glycopyrronium (Seebri), Aclidinium (Tudorza). Block muscarinic M3 receptors on airway smooth muscle, inhibiting acetylcholine-induced bronchospasm. LAMAs reduce exacerbations and hospital admissions significantly more effectively than LABAs and are generally preferred as first-line monotherapy.
• Long-Acting Beta2-Agonists (LABA): Salmeterol (Serevent), Formoterol (Foradil), Indacaterol (Onbrez), Vilanterol (in combinations), Olodaterol (Striverdi). Stimulate beta2-adrenergic receptors, increasing intracellular cyclic AMP and causing smooth muscle relaxation.

2. Dual Bronchodilation (LAMA + LABA Combination)

Combining two bronchodilators with complementary mechanisms provides synergistic bronchodilation, resulting in superior improvements in $FEV_1$, greater reductions in rescue medication use, improved quality of life, and fewer exacerbations compared to either monotherapy alone. Fixed-dose single-inhaler combinations available in Canada include:

• Tiotropium-Olodaterol (Inspiolto Respimat SMI)
• Umeclidinium-Vilanterol (Anoro Ellipta DPI)
• Glycopyrronium-Indacaterol (Ultibro Breezhaler DPI)
• Aclidinium-Formoterol (Duaklir Genuair DPI)

3. Inhaled Corticosteroids (ICS) and Triple Therapy (LAMA + LABA + ICS)

Unlike in asthma, where ICS is foundational first-line therapy, ICS monotherapy is strictly contraindicated in COPD because it does not alter lung function decline or mortality and substantially increases adverse events.

• Indications for Triple Therapy (LAMA + LABA + ICS): Triple therapy (e.g., fluticasone furoate-umeclidinium-vilanterol [Trelegy Ellipta], budesonide-glycopyrronium-formoterol [Breztri Aerosphere]) is recommended by the CTS 2023 guideline for symptomatic patients (CAT ≥ 10 or mMRC ≥ 2) with FEV1 < 80% who are at high risk of exacerbation (≥ 2 moderate or ≥ 1 severe exacerbation in the past year). It can be started directly, without first trying dual therapy. In the CTS meta-analysis, triple therapy reduced exacerbations and all-cause mortality compared with LAMA/LABA. CTS also advises against stepping down from triple to dual therapy in these patients.
• Blood Eosinophils: CTS vs. GOLD:
  • The CTS 2023 recommendations are not gated on blood eosinophils. The panel judged eosinophil data mostly observational, though it notes that patients with ≥ 300 cells/µL are the most likely to benefit, and the most likely to worsen if ICS is withdrawn.
  • The international GOLD report uses eosinophils to decide: it favours adding ICS at ≥ 300 cells/µL (or ≥ 100 with frequent exacerbations), and not adding ICS below 100 cells/µL, adding azithromycin or N-acetylcysteine instead.
  • For a Canadian exam item, follow CTS unless the stem asks about GOLD.
• Adverse Effects & Pneumonia Risk: ICS in COPD increases the risk of pneumonia, along with oral thrush, dysphonia, skin bruising, and mycobacterial infections. The CTS concluded that, in high-risk patients, the mortality and exacerbation benefit of triple therapy outweighs this risk. Pneumonia deaths were not higher with ICS-containing regimens in its meta-analysis.

4. Non-Inhaled Adjunct Therapies

• Phosphodiesterase-4 (PDE-4) Inhibitor (Roflumilast): Daxas 500 mcg PO daily. Reduces intracellular cAMP breakdown in inflammatory cells. Indicated as add-on therapy for patients with severe COPD ($FEV_1 < 50\%$ predicted), chronic bronchitis phenotype (frequent cough and sputum), and recurrent exacerbations despite triple therapy. Adverse effects include nausea, diarrhea, weight loss, and psychiatric events (insomnia, depression).
• Prophylactic Long-Term Macrolide (Azithromycin): Azithromycin 250 mg PO daily or 500 mg PO 3 times weekly for 1 year in former smokers with recurrent exacerbations despite optimized inhaler therapy. Reduces exacerbation rates via immunomodulatory actions. Safety monitoring mandates baseline and periodic ECG monitoring for QT prolongation, audiometry testing for ototoxicity, and surveillance for macrolide-resistant atypical mycobacteria.
• Immunizations: Annual influenza vaccine; one dose of pneumococcal conjugate vaccine (Pneu-C-20 or Pneu-C-21, per NACI); a single dose of respiratory syncytial virus (RSV) vaccine (NACI, April 2026: all adults 75 and older, adults 65 to 74 at increased risk of severe RSV disease, and adults 18 and older who live in long-term care, use home oxygen, receive dialysis, or have had a lung or stem-cell transplant); COVID-19 vaccine as recommended.

---

Acute Exacerbations of COPD (AECOPD): Triage & Pharmacotherapy

An acute exacerbation of COPD is defined as an acute event characterized by a worsening of the patient's respiratory symptoms that is beyond normal day-to-day variations and leads to a change in medication. Over 70% of AECOPD events are triggered by viral or bacterial respiratory tract infections.

The Anthonisen Criteria: Triage for Antibiotic Therapy

In 1987, Anthonisen and colleagues established the clinical classification system that remains the standard in Canadian clinical practice for deciding whether antibiotics are indicated in an exacerbation:

                                  THE THREE ANTHONISEN CARDINAL SYMPTOMS
                                  
                               1. Increased Dyspnea (Shortness of Breath)
                               2. Increased Sputum Volume
                               3. Increased Sputum Purulence (Green / Yellow)
                                                    │
                         ┌──────────────────────────┼──────────────────────────┐
                         ▼                          ▼                          ▼
                   TYPE 1 (Severe)            TYPE 2 (Moderate)          TYPE 3 (Mild)
                 All 3 Cardinal Present      2 of 3 Cardinal Present    1 Cardinal Present +
                         │                          │                  1 Secondary Symptom
                         ▼                          ▼                          │
                   ANTIBIOTICS                PURULENT SPUTUM?                 ▼
                    INDICATED                       │                     ANTIBIOTICS
                                       ┌────────────┴────────────┐       NOT INDICATED
                                       ▼                         ▼        (Supportive care)
                                      YES                       NO
                                       │                         │
                                       ▼                         ▼
                                  ANTIBIOTICS               ANTIBIOTICS
                                   INDICATED               NOT INDICATED

Empiric Antibiotic Stratification (CTS Guidelines)

When indicated, antibiotic therapy should be administered for a duration of 5 days. The selection of empiric therapy is stratified by patient risk factors for treatment failure and resistant pathogens:

Systemic Corticosteroids in AECOPD

• Regimen: Oral prednisone 25 to 50 mg (typically 40–50 mg) once daily for 5 days.
• Evidence: The landmark REDUCE trial demonstrated that a 5-day course of systemic corticosteroid is therapeutically non-inferior to the conventional 14-day course in terms of re-exacerbation rates and time to next exacerbation, while significantly reducing cumulative glucocorticoid exposure, hospital length of stay, and steroid-induced hyperglycemia.

Controlled Oxygen Titration

In acute exacerbations of COPD, supplemental oxygen must be delivered cautiously using a Venturi mask or low-flow nasal prongs titrated to achieve an $SaO_2$ target of 88% to 92% (PaO2 60–70 mmHg). Administering excessive unrestricted oxygen ($SaO_2 > 96\%$) suppresses hypoxic vasoconstriction (worsening ventilation-perfusion mismatch) and diminishes the Haldane effect, precipitating acute respiratory acidosis, severe hypercapnia, CO2 narcosis, coma, and death.

---

Inhaler Delivery Systems: Device Comparison & Technique Counseling

Up to 80% of patients with respiratory disease are unable to use their inhalers correctly, leading to sub-therapeutic lung deposition, poor disease control, and increased emergency presentations. The pharmacist's role in assessing and educating patients on device-specific mechanics is clinically paramount.

                               INHALER DELIVERY DEVICE MECHANICS
                               
    Pressurized MDI (pMDI)             Dry Powder Inhaler (DPI)          Soft Mist Inhaler (SMI)
   ┌───────────────────────┐          ┌───────────────────────┐         ┌───────────────────────┐
   │ • Propellant-driven   │          │ • Breath-actuated     │         │ • Spring-driven cloud │
   │ • Requires coord.     │          │ • Resistance-dependent│         │ • Slow velocity       │
   │ • Slow, deep breath   │          │ • Fast, forceful breath│        │ • Slow, deep breath   │
   │ • Add SPACER (VHC)    │          │ • NO SHAKING; NO WATER│         │ • High lung deposition│
   └───────────────────────┘          └───────────────────────┘         └───────────────────────┘

Comprehensive Inhaler Device Matrix

---

Clinical Case Vignette: Maintenance Optimization & Device Selection in COPD

A 69-year-old male retired construction worker with severe COPD (post-bronchodilator $FEV_1$ 42% predicted; GOLD Grade 3) and a 50 pack-year smoking history visits the clinic pharmacy. His current regimen is tiotropium 18 mcg HandiHaler 1 capsule daily and salbutamol pMDI PRN.

Clinical Assessment:

• Symptom Evaluation: mMRC Dyspnea scale = 3 (stops for breath after walking 80 meters on flat ground). CAT score = 22 (severe impairment). He uses salbutamol 4 to 6 times daily.
• Exacerbation History: Experienced 2 moderate AECOPD episodes over the past 8 months requiring outpatient prednisone and amoxicillin-clavulanate. No hospital admissions.
• Laboratory Biomarkers: Complete blood count (CBC) reveals a total white blood cell count of $6.8 \times 10^9/L$ with blood eosinophils of 80 cells/µL (1.2%).
• Physical Evaluation: The patient has severe osteoarthritis in both hands and struggles with manual dexterity. In-clinic peak inspiratory flow meter (In-Check DIAL) measurement reveals a peak inspiratory flow of only 24 L/min, indicating severe sub-optimal inspiratory effort for dry powder inhalers.

Pharmacotherapeutic Care Plan:

1. Therapeutic Regimen Escalation: The patient is highly symptomatic (CAT 22, mMRC 3) and at high exacerbation risk (2 moderate exacerbations in under a year) on LAMA monotherapy, with FEV1 42%.
2. Is Triple Therapy with an ICS Indicated?: Under CTS 2023, yes. Symptomatic, high-risk patients should receive single-inhaler LAMA/LABA/ICS, regardless of blood eosinophils. His low count (80 cells/µL) means GOLD would instead suggest LAMA/LABA plus azithromycin or N-acetylcysteine, and it predicts a smaller ICS benefit. Discuss pneumonia warning signs, and reassess if he develops pneumonia on ICS.
3. Device Selection Analysis: His HandiHaler DPI is failing because his peak inspiratory flow is only 24 L/min (DPIs require ≥ 30–60 L/min of rapid, forceful effort to deaggregate dry powder), and his severe hand osteoarthritis impairs manipulating and piercing capsules. He requires a device independent of high inspiratory effort.
4. Recommended Prescription Intervention: Switch from tiotropium HandiHaler to a single-inhaler triple therapy that does not need a high inspiratory flow: budesonide-glycopyrronium-formoterol pMDI (Breztri Aerosphere), 2 inhalations twice daily, used with a valved holding chamber. The chamber removes the need to coordinate actuation with a slow inhalation, and a pMDI does not depend on peak inspiratory flow. Because his hand arthritis weakens his grip, add an actuator aid that lets him press the canister with the whole hand, and teach the technique hands-on with teach-back. If he could not manage a pMDI, a soft mist inhaler (Respimat) is the other low-flow option, but no Respimat triple product is available, so it would mean adding a second inhaler.